中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.025 seconds)

    네오헤스페리딘 디하이드로칼콘을 포함하는 동맥경화증,고지혈증, 간 질환, 고혈당증의 예방 및 치료용 조성물
    1.
    发明公开
    네오헤스페리딘 디하이드로칼콘을 포함하는 동맥경화증,고지혈증, 간 질환, 고혈당증의 예방 및 치료용 조성물 失效
    含有NEOHESPERIDIN DIHYDROCHALCONE的组合物可用于预防和治疗ARTERIOSCLEROSIS，HYPERLIPEMIA，肝脏疾病和GLYCOSEMIA

    公开(公告)号：KR1020010007624A

    公开(公告)日：2001-01-26

    申请号：KR1020000058788

    申请日：2000-10-06

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  정태숙 ,  배기환 ,  박용복 ,  최명숙 ,  문석식 ,  권용국 ,  이은숙 ,  현병화 ,  최양규 ,  이철호 ,  안병태 ,  이새봄

    IPC: A61K31/70

    Abstract: PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient's age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.

    Abstract translation: 目的：提供通常用作甜味剂的含有新皮质激素二氢查耳酮的组合物，用于预防和治疗动脉硬化，高脂血症，肝脏疾病和糖血症。 构成：通过从葡萄柚的外层或外层提取或通过化学改变柚皮苷获得新的皮肤色素二氢查耳酮（C28H36O15，M.W.612.60），并且比单位重量的糖更甜1,500-2000倍。 因此，它通常用作不是药用材料的甜味剂。 将包含有效量的新橙皮苷二氢查耳酮，即0.1至500mg / kg，优选1至100mg / kg每天的组合物口服或局部施用于患者，并且施用量可以由患者的年龄， 体重，性别，健康，饮食，疾病严重程度等。 含有新橙皮苷二氢查耳酮的组合物可以以diosmin的0.01〜20重量％，优选0.1〜5重量％的量添加到食品和饮料中。

    탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물
    2.
    发明公开
    탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물 无效
    包含从鞣剂衍生的鞣制或酚醛化合物的组合物，用于预防和治疗高脂血症，肠梗塞和肝病

    公开(公告)号：KR1020000019718A

    公开(公告)日：2000-04-15

    申请号：KR1019980037961

    申请日：1998-09-15

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  정태숙 ,  배기환 ,  박용복 ,  최명숙 ,  문석식 ,  권용국 ,  이은숙 ,  현병화 ,  최양규 ,  이철호 ,  안병태 ,  이새봄

    IPC: A61K31/045

    CPC classification number: A23G3/368 ,  A21D2/14 ,  A21D2/145 ,  A21D2/181 ,  A21D2/36 ,  A23C9/152 ,  A23F3/14 ,  A23L2/56 ,  A23L33/105 ,  A61K31/70 ,  Y10S514/824 ,  A61K31/35 ,  A61K31/19 ,  A61K2300/00

    Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising tannin or phenol-type compounds derived from tannin are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises tannin, gallic acid, ellagic acid or their mixture in effective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of tannin, gallic acid, ellagic acid or their mixture. Tannin, gallic acid and ellagic acid reduce the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase), gamma GTP (gamma-glutamyl transpeptidase) and a lipid in blood, and inhibit the damage of a liver cell and the formation of a fatty liver. Also tannin, gallic acid and ellagic acid strongly inhibit the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.

    Abstract translation: 目的：提供包含单宁衍生的单宁或酚型化合物的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化和肝脏疾病。 构成：药物组合物含有有效量的单宁，没食子酸，鞣花酸或其混合物; 和药学上可接受的载体。 功能性食品或饮料包含0.01-20重量％，优选0.1-5重量％的单宁，没食子酸，鞣花酸或其混合物。 单宁，没食子酸和鞣花酸降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶），γGTP（γ-谷氨酰转肽酶）和血脂中的血清浓度，抑制肝细胞损伤 并形成脂肪肝。 单宁，没食子酸和鞣花酸强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面。

    대추추출물및감귤류과피추출물을포함하는지질대사개선및혈압강하용조성물
    3.
    发明授权
    대추추출물및감귤류과피추출물을포함하는지질대사개선및혈압강하용조성물 失效

    公开(公告)号：KR100296250B1

    公开(公告)日：2001-10-25

    申请号：KR1019980012818

    申请日：1998-04-10

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  손광희 ,  정태숙 ,  배기환 ,  박용복 ,  최명숙 ,  권용국 ,  현병화 ,  최양규 ,  이철호 ,  문석식

    IPC: A61K36/725 ,  A61K36/752 ,  A61P3/06 ,  A61P9/12

    Abstract: PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.

    네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물
    4.
    发明公开
    네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물 失效
    包含NEOHESPERIDIN DIHYDROCHALCONE的组合物，用于预防和治疗高脂血症，肠梗塞，肝病和高血压

    公开(公告)号：KR1020000019720A

    公开(公告)日：2000-04-15

    申请号：KR1019980037963

    申请日：1998-09-15

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  정태숙 ,  배기환 ,  박용복 ,  최명숙 ,  문석식 ,  권용국 ,  이은숙 ,  현병화 ,  최양규 ,  이철호 ,  안병태 ,  이새봄

    IPC: A61K31/70 ,  A23L2/04

    CPC classification number: A23G9/34 ,  A21D2/181 ,  A23C9/152 ,  A23L2/52 ,  A23L27/36 ,  A23L33/105

    Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.

    Abstract translation: 目的：提供一种包含二氢查耳酮中新月皮的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化，肝脏疾病和高血糖症。 组成：药物组合物含二氢查耳酮中的新皮肤无效量; 和药学上可接受的载体。 功能性食品或饮料包含二氢查耳酮中的新鲜皮肤的0.01-20重量％，优选0.1-5重量％。 新橙皮苷二氢查耳酮降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶）和血液中的脂质的浓度，抑制与生物合成相关的还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶） 的胆固醇和ACAT（酰基CoA;胆固醇-O-酰基转移酶），其将胆固醇转化为胆固醇酯，并且抑制肝细胞的损伤和脂肪肝的形成。 二氢查耳酮中的新生皮肤也强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面，并降低血糖浓度。

    바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
    5.
    发明公开
    바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 无效
    包含用于降低血糖的生物素化合物的组合物

    公开(公告)号：KR1020000019716A

    公开(公告)日：2000-04-15

    申请号：KR1019980037958

    申请日：1998-09-15

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  정태숙 ,  배기환 ,  박용복 ,  최명숙 ,  문석식 ,  권용국 ,  이은숙 ,  현병화 ,  최양규 ,  이철호 ,  안병태 ,  이새봄

    IPC: A61K31/70

    CPC classification number: A61K31/34 ,  Y10S514/866

    Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.

    Abstract translation: 目的：提供包含生物类黄酮化合物的药物组合物和功能性食品，用于降血糖。 构成：药物组合物包含有效量的式1所示的生物类黄酮化合物; 和药学上可接受的载体。 在式1中，R 1表示OH，芸香酰基或脱氨基糖基，R 2表示H，OH或芸香糖基，R 3表示H或OH基，R 4表示OH或方法基，X表示单 债券或双重债券。 功能性食品包含0.01-50重量％，优选0.05-10重量％的生物类黄酮化合物。 式1的化合物降低血糖，因此可用于治疗或预防高血糖症。

Patent Agency Ranking